Jean-Charles Nault received his MD and PhD from Paris Descartes University. He is currently working in the liver unit of the Jean Verdier Hospital in Bondy, France with a high priority on early detection of primary liver tumors and on therapeutic innovation. He is also an active member of the Laboratory of Functional Genomics of Solid Tumours at the INSERM UMR 1162 headed by Professor Jessica-Zucman Rossi. His research is dedicated to translational research in particular the identification of new driver genes in hepatocellular adenoma and hepatocellular carcinoma, of new therapeutic targets and of the molecular determinants of hepatocellular carcinoma’s prognosis.
Relevant publications
Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, Bacq Y, Calderaro J, Paradis V, Ramos J, Scoazec JY, Gnemmi V, Sturm N, Guettier C, Fabre M, Savier E, Chiche L, Labrune P, Selves J, Wendum D, Pilati C, Laurent A, De Muret A, Le Bail B, Rebouissou S, Imbeaud S; GENTHEP investigators., Bioulac-Sage P, Letouzé E, Zucman-Rossi J. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology 2016 Dec 7.
Nault JC. The end of almost 10 years of negative RCTs in advanced hepatocellular carcinoma.
Lancet 2017 Jan 7; 389(10064): 4-6.
Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouzé E, Pilati C, Verret B, Blanc JF, Balabaud C, Calderaro J, Laurent A, Letexier M, Bioulac-Sage P, Calvo F, Zucman-Rossi J. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet 2015 Oct; 47(10): 1187-93.
Nault JC, Calderaro J, Di Tommaso L, Balabaud C, Zafrani ES, Bioulac-Sage P, Roncalli M, Zucman-Rossi J. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 2014 Dec; 60(6): 1983-92.
Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Balabaud C, Zucman-Rossi J. High frequency of TERT promoter mutations in hepatocellular carcinoma and pre-neoplastic lesions. Nat Commun 2013; 4: 2218. doi: 10.1038/ncomms3218.
Nault JC, de Reyniès A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud S, Rousseau F, Azoulay D, Saric J, Blanc JF, Balabaud C, Bioulac-Sage P, Laurent A, Laurent-Puig P, Llovet JM, Zucman-Rossi J. A hepatocellular carcinoma 5-gene score associated with survival of patients following liver resection. Gastroenterology 2013 Jul; 145(1): 176-87. doi: 10.1053/j.gastro.2013.03.051.
Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 2013 Feb; 144(5): 888-902. doi: 10.1053/j.gastro.2013.02.032.
Nault JC, Fabre M, Couchy G, Pilati C, Jeannot E, Tran Van Nhieu J, Saint-Paul MC, De Muret A, Redon MJ, Buffet C, Salenave S, Balabaud C, Prevot S, Labrune P, Bioulac-Sage P, Scoazec JY, Chanson P, Zucman-Rossi J. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol 2012 Jan; 56(1): 184-91.
Assoc. Prof. Jean-Charles Nault has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
| 
5 min
|
2017 
28 min
